Date: 2014-06-19
Type of information: Treatment of the first patient
phase: 1
Announcement: treatment of the first patient
Company: Servier (France) Vernalis (UK)
Product: undisclosed selective BCL-2 inhibitor
Action
mechanism: BCL-2 selective inhibitor. Proteins of the BCL-2 family are crucial regulators of apoptosis. Deregulations of this protein family play a major role in the aberrant survival of tumour cells. Within this protein family, BCL-2 belongs to the pro-survival members and is often overexpressed in tumour cells. Pro-survival BCL-2 family members have been recognized as attractive therapeutic targets in oncology for more than twenty years but drug discovery research on this class of target is particularly challenging and requires innovative chemistry supported by structural biology.
Disease:
Therapeutic area: Cancer - Oncology
Country:
Trial details:
Latest
news: * On June 19, 2014, Vernalis and Servier announce the achievement of a milestone following the treatment of the first patient in a Servier sponsored Phase I trial with a promising new drug candidate, a selective BCL-2 inhibitor identified through their joint oncology drug discovery collaboration. As a result, Vernalis will receive a payment of €1.0 million in recognition of this achievement. This BCL-2 selective inhibitor is the first drug candidate stemming from an on-going collaboration between Vernalis and Servier aimed at discovering anticancer drug candidates selective for individual BCL-2 family members.
